Revia

Pruritus, Caloric Restriction, BMI >27 kg/m2 + 8 more

Treatment

5 FDA approvals

20 Active Studies for Revia

Treatment for

Pruritus

What is Revia

NaltrexoneThe Generic name of this drug

Treatment SummaryNaltrexone is a drug derived from noroxymorphone and is used to block the effects of narcotics and alcohol. It is more potent and longer lasting than naloxone, which makes it a good treatment for heroin addiction. Naltrexone has been approved by the FDA to treat alcohol dependence.

Naltrexone Hydrochlorideis the brand name

image of different drug pills on a surface

Revia Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Naltrexone Hydrochloride

Naltrexone

1998

59

Approved as Treatment by the FDA

Naltrexone, otherwise known as Naltrexone Hydrochloride, is approved by the FDA for 5 uses including Alcoholism and Opioid Dependence .

Alcoholism

Helps manage Alcohol Dependency

Opioid Dependence

Helps manage Opioid Dependence

Pain

Used to treat Severe Pain in combination with Morphine

Therapeutic procedure

Used to treat inadequate alternative treatment options in combination with Morphine

Opiate Substitution Treatment

Used to treat requiring long-term opioid treatment in combination with Morphine

Effectiveness

How Revia Affects PatientsNaltrexone is a drug that blocks the effects of opioids in the body and is used to treat alcohol dependence. It stops the body from feeling the effects of opioids taken externally and blocks physical dependence on them. When taken with opioids, it can cause withdrawal symptoms in those who are physically dependent on them.

How Revia works in the bodyNaltrexone is a drug that blocks the effects of opioids in the brain. It does this by attaching itself to opioid receptors, which prevents other molecules, like endorphins, from binding to them. This stops the effects opioids have on the body, like pain relief, miosis, and respiratory depression. The major metabolite of naltrexone, 6-β-naltrexol, also has opioid blocking activity. It is unclear how it works to help treat alcoholism.

When to interrupt dosage

The serving of Revia is contingent upon the diagnosed problem, including Opioid Dependence, a reduced-calorie diet, and BMI >27 kg/m2. The measure of dosage diverges as per the method of delivery shown in the accompanying table.

Condition

Dosage

Administration

Pruritus

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Caloric Restriction

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

BMI >27 kg/m2

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Increased physical activity levels

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Opioid Dependence

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Pain

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Alcoholism

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Opiate Substitution Treatment

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Comorbidity

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Chronic Weight Management therapy

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Therapeutic procedure

, 50.0 mg, 0.8 mg, 1.2 mg, 2.0 mg, 4.0 mg, 2.4 mg, 3.2 mg, 8.0 mg, 4.8 mg, 3.6 mg, 7.2 mg, 9.6 mg, 380.0 mg, 200.0 mg, 380.0 mg/mL, 90.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Kit, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Subcutaneous, Implant, Implant - Subcutaneous, Intramuscular, Kit - Intramuscular

Warnings

Revia Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Withdrawal syndrome

Do Not Combine

Adrenal gland hypofunction

Do Not Combine

There are 20 known major drug interactions with Revia.

Common Revia Drug Interactions

Drug Name

Risk Level

Description

Eluxadoline

Major

The risk or severity of constipation can be increased when Naltrexone is combined with Eluxadoline.

Methylene blue

Major

Naltrexone may increase the serotonergic activities of Methylene blue.

Methylnaltrexone

Major

Naltrexone may increase the opioid antagonism activities of Methylnaltrexone.

Mirtazapine

Major

Naltrexone may increase the serotonergic activities of Mirtazapine.

Naloxegol

Major

Naltrexone may increase the opioid antagonism activities of Naloxegol.

Revia Toxicity & Overdose RiskAnimals have a toxic dose of naltrexone between 1100-1550mg/kg for mice, 1450mg/kg for rats, and 1490mg/kg for guinea pigs. Taking very high doses of naltrexone (generally more than 1000mg/kg) can cause drooling, reduced energy levels, tremors, and seizures.

image of a doctor in a lab doing drug, clinical research

Revia Novel Uses: Which Conditions Have a Clinical Trial Featuring Revia?

Currently, 30 active studies are being conducted to assess the effectiveness of Revia in conjunction with a reduced-calorie diet, Pruritus alleviation and increased physical activity.

Condition

Clinical Trials

Trial Phases

Increased physical activity levels

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Pruritus

0 Actively Recruiting

Opioid Dependence

14 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1

Opiate Substitution Treatment

0 Actively Recruiting

Pain

0 Actively Recruiting

BMI >27 kg/m2

0 Actively Recruiting

Caloric Restriction

0 Actively Recruiting

Comorbidity

0 Actively Recruiting

Revia Reviews: What are patients saying about Revia?

5Patient Review

2/21/2014

Revia for Prevention of Opiate Drug Abuse

I'm so glad I found this medication! It's been a month and it's working great for me with no side effects. I was using opiates and heroin before, but this pill has been a miracle for me.

5Patient Review

3/23/2009

Revia for Prevention of Opiate Drug Abuse

5Patient Review

1/11/2010

Revia for Prevention of Opiate Drug Abuse

I would like to learn more about this medication.

4.7Patient Review

1/13/2010

Revia for Habit of Drinking Too Much Alcohol

My fiance was an opiate addict for 3 years. He went to rehab and they gave him revia, which caused withdrawal symptoms for the first few days. But he tough it out and now he's been clean for a year! He's made so much progress and is the man I fell in love with again.

4.7Patient Review

5/13/2009

Revia for Prevention of Opiate Drug Abuse

I felt pretty bad after taking this, with diarrhea and still feeling cravings for Lortab.

4.3Patient Review

4/19/2015

Revia for Habit of Drinking Too Much Alcohol

Don't give up on this medication! It really does work, but it may take some time to see results.

4Patient Review

3/20/2011

Revia for Habit of Drinking Too Much Alcohol

I have never tried this treatment before.

3Patient Review

5/13/2011

Revia for Habit of Drinking Too Much Alcohol

I've only taken this medication twice, but I was very nauseous afterwards both times. The second time, I didn't even have dinner because the nausea was so severe. Finally threw up before going to bed. while this pill does seem to be effective as an appetite suppressant, the side effects are not worth it in my opinion.

3Patient Review

8/8/2008

Revia for Habit of Drinking Too Much Alcohol

2.7Patient Review

10/26/2013

Revia for Prevention of Opiate Drug Abuse

I'm not sure what to make of this treatment yet. I only just started taking it last night, so it's too early to tell if it's working or not. They prescribed it to me for cravings, and so far I haven't had any pain medication in 30 days.

1.3Patient Review

8/4/2011

Revia for Prevention of Opiate Drug Abuse

I was given this medication to help with cravings, and I'm now two months clean. However, the side effects were really bad. I constantly felt nauseous, my jaw was clenched all the time, I had headaches and chest pain. Additionally, I lost my appetite and just generally felt sick. I don't think I'll be taking this medication anymore.

1Patient Review

2/22/2016

Revia for Habit of Drinking Too Much Alcohol

I'm about to start this table, but I have an alcohol problem. Are there any other people out there taking it for alcohol?

1Patient Review

8/2/2008

Revia for Prevention of Opiate Drug Abuse

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about revia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between ReVia and Vivitrol?

"The only form of naltrexone that is FDA-approved for treating opioid use disorder is the injectable form, Vivitrol. Naltrexone in any form will block the effects of opioid drugs. Taking naltrexone reduces your tolerance to opioids."

Answered by AI

What is the meaning of ReVia?

"This drug blocks the action of opiates, which are drugs used to treat pain. It may be used to treat intravenous opiate addiction or alcohol dependence."

Answered by AI

How does naltrexone make you feel?

"Naltrexone works by blocking the parts of the brain that are associated with pleasure from alcohol and drugs. By doing this, it makes it easier to stop drinking."

Answered by AI

How do you use ReVia?

"This medicine is taken by mouth, with or without food. The usual dose is 50 mg per day. You may be monitored by a health care professional when taking this medicine."

Answered by AI

Clinical Trials for Revia

Image of Washington State University in Spokane, United States.

Virtual Incentive Treatment for Alcoholism

This trial aims to use a blood test biomarker called phosphatidylethanol (PEth) to detect alcohol use for up to 28 days. The study will involve 200 adults with

Waitlist Available

Washington State UniversitySean Murphy, PhD

Image of University of Pennsylvania Center for Studies of Addiction in Philadelphia, United States.

Kenetik for Ketosis

Philadelphia, PA

This trial tests if a ketone supplement can reduce symptoms of alcohol withdrawal during treatment.

Waitlist Available

Dietary Supplement

University of Pennsylvania Center for Studies of Addiction (+1 Sites)Corinde E Wiers, Ph.D.

Image of MindLight, LLC in Newton Highlands, United States.

Unilateral Transcranial Photobiomodulation for Opioid Use Disorder

Newton Highlands, MA

This trial will test a new treatment for opiate addiction using a 4-minute intense near infra-red light therapy on a specific part of the brain. The treatment will be compared to a fake treatment on

MindLight, LLCMindLight, LLC

Image of Hudson Medical in New York, United States.

Anti-inflammatory Supplementation for Chronic Pain

This trial studies how a plant-based supplement affects biomarkers of chronic pain in the urine.

Waitlist Available

Hudson MedicalJonathann Kuo, MDEthos Research & Development

Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.

Explore trials for Revia

Image of Stanford University in Stanford, United States.

Lacosamide for Chronic Pancreatitis

This trial tests an epilepsy drug to see if it can reduce pain when used along with opioids to treat chronic abdominal pain in CP patients. Safety & tolerability will assess if it works.

Stanford University (+4 Sites)Aynur Unalp-Arida, MD, PhD

Image of University of British Columbia - Okanagan Campus in Kelowna, Canada.

Psilocybin-assisted Psychotherapy for Opioid Use Disorder

Kelowna, Canada

This trial tests if a type of psychedelic therapy can help people reduce their opioid use for chronic pain. Participation lasts 8 months and includes two 25mg psilocybin therapy sessions. Outcomes will be tracked for safety & effectiveness.

Waitlist Available

University of British Columbia - Okanagan CampusW. Francois Louw, MD

Image of The University of Texas Health Science Center at Houston in Houston, United States.

Comprehensive Support Program for Opioid Addiction

This trial is testing a new program to help youths with opioid use disorder in Houston. The program includes medication, counseling, and peer support. The goal is to see if this program can help engage and retain more people in treatment.

The University of Texas Health Science Center at HoustonJames R Langabeer, PhD

Image of University of Colorado in Denver, United States.

Medication Assisted Treatment for Opioid Use Disorder

This trial is testing three different ways of beginning treatment for opioid addiction to see which works best. The methods being compared are in-person at a doctor's office, at-home, and through telehealth. The goal is to help people with opioid addiction in primary care settings.

Waitlist Available

University of Colorado (+1 Sites)

Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.

Explore trials for Revia

Image of Sport and Spine Rehab Clinics in Landover, United States.

Duotherm VibraCool Back Device for Opioid Use Disorder

This trial is looking at whether the use of opioids to treat chronic low back pain is effective, and if so, whether a particular type of opioid, DuoTherm, is more effective than a placebo.

Waitlist Available

Sport and Spine Rehab Clinics (+2 Sites)Amy Baxter, MDMMJ Labs LLC

Image of University of Delaware in Newark, United States.

mABC Intervention for Opioid Addiction

This trial will study if the mABC Intervention, adapted for use with peripartum mothers receiving medication-assisted treatment for opioid use disorder, is more effective than a control intervention in improving parenting and infant outcomes.

University of DelawareMary Dozier, Ph.D.

Image of Behavioral Pharmacology Research Unit in Baltimore, United States.

Bridge Device + Lofexidine for Opioid Use Disorder

This trial is designed to study the efficacy of the Bridge Device, a neuromodulator medical device, for the treatment of Opioid Use Disorder. The device was cleared by the FDA based on safety, but not efficacy. The trial will enroll persons with active OUD who will be randomly assigned to one of three conditions: active BD with placebo, sham BD with lofexidine, or sham BD and placebo. The study will monitor participants for withdrawal symptoms and tolerance after device removal.

Behavioral Pharmacology Research UnitEric Strain

Image of Wake Forest School of Medicine in Winston-Salem, United States.

Transcranial Magnetic Stimulation for Alcoholism

Winston-Salem, NC

This trial will test if transcranial magnetic stimulation can help people with alcohol use disorder abstain from drinking.

1 Prior Treatment

Wake Forest School of MedicineColleen Hanlon, PhD

Have you considered Revia clinical trials? We made a collection of clinical trials featuring Revia, we think they might fit your search criteria.

Explore trials for Revia

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security